SCHEMBL24829447

SCHEMBL24829447

CC(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCCN)NC(=O)C(Cc2ccccc2)NC(=O)CCCCCN2C(=O)C=CC2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CALCRL Q16602 2/20 0.51
▸ SSTR3 P32745 1/20 0.47
▸ HRH1 P35367 3/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ MMP3 P08254 1/20 0.41
▸ SIRT2 Q8IXJ6 4/20 0.41
▸ SIRT1 Q96EB6 4/20 0.41
▸ F2 P00734 1/20 0.41
▸ SIRT3 Q9NTG7 2/20 0.40
▸ FAP Q12884 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ ECE1 P42892 1/20 0.40
▸ NPY1R P25929 1/20 0.39
▸ NPY2R P49146 1/20 0.39
▸ NPY4R P50391 1/20 0.39
▸ NPY5R Q15761 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23330068 1.00 CALCRL (0.51) CALCRLSSTR3HRH1HDAC1MMP3
SCHEMBL22910386 0.93 CALCRL (0.51) CALCRLSSTR3HRH1HDAC1MMP3
SCHEMBL23347148 0.92 CALCRL (0.48) CALCRLSSTR3HRH1HDAC1MMP3
SCHEMBL24164777 0.92 CALCRL (0.50) CALCRLSSTR3HDAC1SIRT2SIRT1
SCHEMBL24829565 0.91 CALCRL (0.49) CALCRLSSTR3HRH1HDAC1MMP3
SCHEMBL27058431 0.91 CALCRL (0.55) CALCRLSSTR3HRH1F2NPY1R
SCHEMBL23347260 0.89 CALCRL (0.47) CALCRLSSTR3HRH1HDAC1MMP3
SCHEMBL24829473 0.89 SSTR3 (0.57) CALCRLSSTR3SIRT2SIRT1SIRT3
SCHEMBL21065668 0.88 FAP (0.42) CALCRLSIRT2SIRT1SIRT3FAP
SCHEMBL19709466 0.88 FAP (0.42) CALCRLSIRT2SIRT1SIRT3FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11541126-B1 Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof SILVERBACK THERAPEUTICS, INC. (US) 2023-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541126-B1 Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof ASGR1, TLR8, HAVCR2 CALCRL 1791/4885SSTR3 1768/4885HRH1 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback